MedTrace Logo

Hypofractionated Radiotherapy for Thymic Epithelial Tumors

NCT06692062 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-11-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are:

* Does Hypofractionated radiotherapy provide better results?
* Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery.

Participants will:

* Receive hypofractionated radiotherapy or conventional radiotherapy
* Visit the hospital regularly once every 12 weeks for checkups and tests

Conditions

  • Thymoma and Thymic Carcinoma
  • Thymoma
  • Thymic Cancer
  • Thymic Epithelial Tumor

Interventions

RADIATION

Hypofractionated Radiation Therapy

R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f

Sponsors & Collaborators

  • Rongrong Zhou

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2027-11-01
Completion
2027-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06692062 on ClinicalTrials.gov